ArticleBreast cancer (Tokyo, Japan)2024
Reply to comment on 'An increase in tumor-infiltrating lymphocytes after treatment is significantly associated with a poor response to neoadjuvant endocrine therapy for estrogen receptor-positive/HER2-negative breast cancers' by Fukui et al.
Reiko Fukui et al.PubMed ↗Publisher ↗
No numbers read from the abstract.